A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prodrug BMS-986465 and Its Active Derivative, BMS-986464, in Healthy Participants Including Healthy Participants of Japanese Ethnicity and an Open-label Assessment of Food, Formulation, and pH Effects on the Relative Bioavailability of BMS-986465 and BMS-986464

The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity.

Inclusion Criteria:

• Healthy male and female (i e, women not of childbearing potential) participants
• Body Mass Index (BMI) of 18 to 32 kg^m2 and total body weight ≥ 50 kg
• Parts A, B, and D: Participants without restriction on ethnicity
• Part C: Participants of Japanese ethnicity (both biological parents are ethnically Japanese)

Exclusion Criteria:

• Clinically significant medical, psychiatric and/or sound social reason, as determined by the investigator
• Any major surgery within 3 months of study intervention administration
• Participation in another clinical trial concurrent with this study

Note: Other protocol-defined inclusion/exclusion criteria apply